MRNA vs. TEM: Moderna vs. Tempus AI Stock Comparison

Company Profile

Moderna (MRNA) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MRNA is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Moderna (MRNA) has been public since December 7, 2018, giving it a longer listed trading history, while Tempus AI (TEM) listed on June 14, 2024 and still has a shorter public-market record.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Moderna (MRNA) is closer to market-like at 1.08 — a noticeable difference in market-sensitivity profile.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Moderna (MRNA) at -39.00% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

Both Moderna (MRNA) at -141.43% and Tempus AI (TEM) at -12.54% report negative net margin values, usually indicating net losses over the period.

Both Moderna (MRNA) at -557.93% and Tempus AI (TEM) at -13.82% report negative operating margin values, usually indicating operating losses over the period.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Moderna (MRNA) at -39.92% is in the bottom quartile, showing a clear gap in revenue momentum.

Neither Moderna (MRNA) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRNA.

Moderna (MRNA) at 0.19 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Moderna (MRNA) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Moderna (MRNA) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neither Moderna (MRNA) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

Tempus AI (TEM) at 9.19 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.

Both look rich against book: Moderna (MRNA) at 11.58 sits in the upper P/B ratio quartile, and Tempus AI (TEM) at 27.66 prices even higher, above its industry range.

Valuation Metrics